Skip to main content
SpringerLink
Log in

Homozygous Deletion of INK4a/ARF Genes and Overexpression of Bcl-2 in Relation with Poor Prognosis in Immunocompetent Patients with Primary Central Nervous System Lymphoma of the Diffuse Large B-cell Type

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Only a few reports have been published on molecular genetic alterations in primary central nervous system lymphomas (PCNSLs) of the diffuse large B-cell type and no reports have addressed the correlation between the genetic alterations and clinical course of the patients with this neoplasm. Thus, the molecular background of the PCNSL and its importance for the clinical course of the patients are still unclear. We investigated a series of 14 patients with PCNSL to determine structural alterations of the INK4a/ARF, MDM2, and TP53 genes, the status of bcl-2 and bcl-6 protein expression, and the clinical course of the patients (i.e. their survival time after diagnosis). No structural alterations of MDM2 and TP53 genes were found. Only INK4a/ARF genes whose expression affects both the p16INK4a–Rb and p14ARF–mdm2–p53 pathways in the regulation for cell cycle and apoptosis, showed an alteration of the homozygous deletions at a high frequency (nine of 14 patients: 64%). This specific alteration was not related with the bcl-6 expression, but a relation was shown with overexpression of the bcl-2 anti-apoptotic protein (p = 0.036, chi-square test), as well as a shorter patient survival (p = 0.044, Wilcoxon test). There was only a tendency, not a significant correlation, in which the patients with bcl-2 overexpression resulted in poor prognosis (p = 0.149). The present study is the first to suggest that the INK4a/ARF gene homozygous deletions and overexpression of the bcl-2 protein may be correlated with each other and together serve as important predictors for the prognosis of patients with PCNSL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Henry JM, Heffner RR Jr, Dillard SH, Earle KM, Davis RL: Primary malignant lymphomas of the central nervous system. Cancer 34: 1293–1302, 1974

    Google Scholar 

  2. Jellinger K, Radaskiewicz TH, Slowik F: Primary malignant lymphomas of the central nervous system in man. Acta Neuropathol Suppl (Berl) Suppl: 95–102, 1975

  3. Zimmerman HM: Malignant lymphomas of the nervous system. Acta Neuropathol Suppl (Berl) Suppl: 69–74, 1975

  4. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H: Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 74: 1383–1397, 1994

    Google Scholar 

  5. Grant JW, Isaacson PG: Primary central nervous system lymphoma. Brain Pathol 2: 97–109, 1992

    Google Scholar 

  6. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Müller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361–1392, 1994

    Google Scholar 

  7. Morgello S: Pathogenesis and classification of primary central nervous system lymphoma: an update. Brain Pathol 5: 383–393, 1995

    Google Scholar 

  8. Baur A, Shaw P, Burri N, Delacretaz F, Bosman F, Chaubert P: Frequent methylation silencing of p15INK4b (MTS2) and p16INK4a (MTS1) in B-cell and T-cell lymphomas. Blood 94: 1773–1781, 1999

    Google Scholar 

  9. Cobbers JMJL, Wolter M, Reifenberger J, Ring GU, Jessen F, An H-X, Niederacher D, Schmidt EE, Ichimura K, Floeth F, Kirsch L, Borchard F, Louis DN, Collins VP, Reifenberger G: Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol 8: 263–276, 1998

    Google Scholar 

  10. Pinyol M, Hernandez L, Martinez A, Cobo F, Hernandez S, Bea S, Lopez-Guillermo A, Nayach I, Palacin A, Nadal A, Fernandez P, Montserrat E, Cardesa A, Campo E: INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 156: 1987–1996, 2000

    Google Scholar 

  11. Villuendas R, Sáchez-Beato M, Martínez JC, Saez AI, Martinez-Delgado B, García JF, Mateo MS, Sanchez-Verde L, Benítez J, Martínez P, Piris MA: Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol 153: 887–897, 1998

    Google Scholar 

  12. Zhang S-J, Endo S, Ichikawa T, Washiyama K, Kumanishi T: Frequent deletion and 5′ CpG island methylation of the p16 gene in primary malignant lymphoma of the brain. Cancer Res 58: 1231–1237, 1998

    Google Scholar 

  13. Ichikawa A, Hotta T, Takagi N, Tsushita K, Kinoshita T, Nagai H, Murakami Y, Hayashi K, Saito H: Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 79: 2701–2707, 1992

    Google Scholar 

  14. Kawamata N, Miller C, Levy V, Shintaku I, Koeffler H, Said J: mdm2 oncogene expression in non-Hodgikin's lymphomas. Diagn Mol Pathol 5: 33–38, 1996

    Google Scholar 

  15. Moller M, Ino Y, Gerdes A, Skjodt K, Louis D, Pedersen N: Aberrations of the p53 pathway components p53, MDM2 and CDKN2 appear independent in diffuse large B cell lymphoma. Leukemia 13: 453–459, 1999

    Google Scholar 

  16. Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, Popplewell L, Offit K, Jhanwar SC, Chaganti RSK: Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 92: 234–240, 1998

    Google Scholar 

  17. Bairey O, Zimra Y, Shaklai M, Okon E, Rabizadeh E: Bcl-2, Bcl-X, Bax, and Bak expression in short-and long-lived patients with diffuse large B-cell lymphomas. Clin Cancer Res 10: 2860–2866, 1999

    Google Scholar 

  18. Gascoyne R, Adomat S, Krajewski S, Krajewski M, Horsman D, Tolcher A, O'Reilly S, Hoskins P, Goldman A, Reed J, Connors J: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgikin's lymphoma. Blood 90: 244–251, 1997

    Google Scholar 

  19. Monni O, Franssila K, Joensuu H, Knuutila S: BCL2 overexpression in diffuse large B-cell lymphoma. Leuk Lymphoma 34: 45–52, 1999

    Google Scholar 

  20. Offit K, Coco FL, Louie DC, Parsa NZ, Leung D, Portlock C, Ye BH, Lista F, Filippa DA, Rosenbaum A, Ladanyi M, Jhanwar S, Dalla-Favera R, Chaganti RSK: Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 331: 74–80, 1994

    Google Scholar 

  21. Reed J, Kitada S, Takayama S, Miyashita T: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgikin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5: 61–65, 1994

    Google Scholar 

  22. Camilleri-Broet S, Martin A, Moreau A, Angonin R, Henin D, Gontier MF, Rousselet MC, Caulet-Maugendre S, Cuilliere P, Lefrancq T, Mokhtari K, Morcos M, Broet P, Kujas M, Hauw JJ, Desablens B, Paphael M: Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol 110: 607–612, 1998

    Google Scholar 

  23. Krogh-Jensen M, Johansen P, D'Amore F: Primary central nervous system lymphomas in immunocompetent individuals: histology, Epstein-Barr virus genome, Ki-67 proliferation index, p53 and bcl-2 gene expression. Leuk Lymphoma 30: 131–142, 1998

    Google Scholar 

  24. Iwato M, Tachibana O, Tohma Y, Arakawa Y, Nitta H, Hasegawa M, Yamashita J, Hayashi Y: Alterations of the INK4a/ARF locus in human intracranial germ cell tumors. Cancer Res 60: 2113–2115, 2000

    Google Scholar 

  25. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353–6358, 1994

    Google Scholar 

  26. Iwato M, Tachibana O, Tohma Y, Nitta H, Hayashi Y, Yamashita J: Molecular analysis for p53 and mdm2 in intracranial germ cell tumors. Acta Neuropathol (Berl) 99: 21–25, 2000

    Google Scholar 

  27. Moller M, Kania P, Ino Y, Gerdes A, Nielsen O, Louis D, Skjodt K, Pedersen N: Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic signifi-cance of E2F-1 and p16INK4A. Leukemia 14: 898–904, 2000

    Google Scholar 

  28. Sherr CJ: Tumor surveillance via the ARF-p53 pathway. Genes Dev 12: 2984–2991, 1998

    Google Scholar 

  29. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T Jr, JH, Lu L, Lewis DB, Tibshirani R, Sherlock G, Wing CC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct type of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503–511, 2000

    Google Scholar 

  30. Ohno H, Fukuhara S: Significance of rearrangement of the BCL6 gene in B-cell lymphoid neoplasms. Leuk Lymphoma 27: 53–63, 1997

    Google Scholar 

  31. Seyfert V, Allman D, He Y, Staudt L: Transcriptional repression by the proto-oncogene BCL-6. Oncogene 12: 2331–2342, 1996

    Google Scholar 

  32. Reed J: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1–6, 1994

    Google Scholar 

  33. Kataoka M, Wiehle S, Spitz F, Schumacher G, Roth J, Cristiano R: Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells. Oncogene 19: 1589–1595, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Kanazawa University School of Medicine, Kanazawa, Japan

    Yutaka Hayashi, Masayuki Iwato, Yasuaki Arakawa, Hironori Fujisawa, Yasuo Thoma, Mitsuhiro Hasegawa, Osamu Tachibana & Junkoh Yamashita

Authors
  1. Yutaka Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masayuki Iwato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuaki Arakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hironori Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasuo Thoma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mitsuhiro Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Osamu Tachibana
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Junkoh Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hayashi, Y., Iwato, M., Arakawa, Y. et al. Homozygous Deletion of INK4a/ARF Genes and Overexpression of Bcl-2 in Relation with Poor Prognosis in Immunocompetent Patients with Primary Central Nervous System Lymphoma of the Diffuse Large B-cell Type. J Neurooncol 55, 51–58 (2001). https://doi.org/10.1023/A:1012946812930

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012946812930

Search

Navigation